Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Induction of Anti-Mammary Cancer Immunity by Engaging the OX-40 Receptor in Vivo
Authors
Arden Morris
John T. Vetto
Trygg Ramstad
Castle J. Funatake
Esther Choolun
Claire Entwisle
Andrew D. Weinberg
Publication date
01-05-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1010649303056

Other articles of this Issue 1/2001

Breast Cancer Research and Treatment 1/2001 Go to the issue

Conference Report

Inhibition of Human Breast Cancer Cell Growth by Blockade of the Mevalonate-Protein Prenylation Pathway is not Prevented by Overexpression of Cyclin D1

Conference Report

Contralateral Breast Cancer: Molecular Differentiation Between Metastasis and Second Primary Cancer

BriefCommunication

Expression of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Breast Carcinoma

Conference Report

Low pO2 and β-Estradiol Induce VEGF in MCF-7 and MCF-7-5C Cells: Relationship to in vivo Hypoxia

Conference Report

Sealing of Postoperative Axillary Leakage After Axillary Lymphadenectomy Using a Fibrin Glue Coated Collagen Patch: a Prospective Randomised Study

Conference Report

Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits